Advanced search
Publication Cover
Modern Rheumatology Volume 19, 2009 - Issue 2
Journal homepage
31
Views
17
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren’s syndrome: a double-blind placebo-controlled multicenter trial

Susumu SugaiKanazawa Medical University, Ishikawa, Japan; 17 Nagamachi, Daishouji, Kaga, Ishikawa 922-0024, JapanCorrespondence[email protected]
,
Hiroki TakahashiFirst Department of Internal Medicine, Sapporo Medical University School of Medicine, Hokkaido, Japan
,
Shuji OhtaDepartment of Rheumatology, Taga General Hospital, Ibaraki, Japan
,
Makoto NishinaritaDivision of Rheumatology, Nishinarita Clinic Office, Ibaraki, Japan
,
Masami TakeiDivision of Hematology and Rheumatology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan
,
Shigemasa SawadaDivision of Hematology and Rheumatology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan;Division of Rheumatology, Department of Medicine, Nihon University Nerima Hikarigaoka Hospital, Tokyo, Japan
,
Ken YamajiDepartment of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
,
Hiroshi OkaInstitute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan
,
Hisanori UmeharaDivision of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan
,
Ichiro KoniDivision of Rheumatology, Department of Internal Medicine, Kanazawa University Graduate School of Medicine, Ishikawa, Japan
,
Eiji SugiyamaDepartment of Internal Medicine 1, Faculty of Medicine, University of Toyama, Toyama, Japan
,
Susumu NishiyamaRheumatic Disease Center, Kurashiki Medical Center, Okayama, Japan
&
Atsushi KawakamiDepartment of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
 show all
Pages 114-124 | Received 09 Jul 2008, Accepted 23 Oct 2008, Published online: 02 Jan 2014

References

  • Moutsopoulos HM. Sjogren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol. 1994;72:162–5.
  • Fox RI. Sjogren's syndrome. Lancet. 2005;366:321–31.
  • Ramos-Casals M, Brito-Zer6n P. New approaches in Sjogren's syndrome therapy. Expert Rev Clin Immunol. 2007;3:195–204.
  • Thanou-Stavraki A, James JA. Primary Sjogren's syndrome: current and prospective therapies. Semin Arthritis Rheum. 2008;37:273–92.
  • Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57: 310–7.
  • Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Bene R, Bordron A, et al. BAFF-modulated repopulation of B lympho-cytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum. 2007;56:1464–77.
  • Nakayamada S, Saito K, Nakatsuka K, Nakano K, Tokunaga M, Sawamukai N, et al. Efficacy of mizoribine treatment in patients with Sjogren's syndrome: an open pilot trial. Mod Rheumatol. 2003;13:339–45.
  • Nakayamada S, Saito K, Umehara H, Ogawa N, Sumida T, Ito S, et al. Efficacy and safety of mizoribine for the treatment of Sjogren's syndrome: a multicenter open-label clinical trial. Mod Rheumatol. 2007;17:464–9.
  • Arakawa T, Kobayashi K, Yoshikawa T, Tamawski A. Reb-amipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43:55-13S.
  • Arakawa T, Higuchi K, Fujiwara Y, Watanabe T, Tominaga K, Sasaki E, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50:53–S11.
  • Kohashi M, Ishimaru N, Arakai R, Hayashi Y. Effective treat-ment with oral administration of rebamipide in a mouse model of Sjogren's syndrome. Arthritis Rheum. 2008;58:389–400.
  • Oka H, Nakano H, Kimata T, Matsuda T, Ozaki S. Effect of rebamipide for the treatment of xerostomia in patients with Sjö-gren's syndrome. Progr Med. 2004;24:205–10.
  • Kohler PF, Winter ME. A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum. 1985;28:1128–32.
  • Strong B, Farley W, Stem ME, Pflugfelder SC. Topical cyclo-sporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea. 2005;24:80–5.
  • Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum. 2003;49:585–93.
  • Smith JK, Siddiqui AA, Modica LA, Dykes R, Simmons C, Schmidt J, et al. Interferon-alpha upregulates gene expression of aquaporin-5 in human parotid glands. J Interferon Cytokine Res. 1999;19:929–35.
  • Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of primary Sjogren's syndrome with hydroxychloro-quine. Am J Med. 1988;85:62–7.
  • Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjogren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis. 1999;58:253–6.
  • Miyawaki S, Nishiyama S, Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjogren's syndrome. Intern Med. 1999;38:938–43.
  • Zandbelt MM, van den Hoogen FH, de Wilde PC, van den Berg PJ, Schneider HG, van de Putte LB. Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatment with corticosteroids in Sjogren's syndrome. Ann Rheum Dis. 2001;60:511–3.
  • Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M. Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci. 1998;43:160S–6S.
  • Yoshikawa T, Naito Y, Tanigawa T, Kondo M. Free radical scavenging activity of the novel anti-ulcer agent rebamipide Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea. 2004;23:613–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.